{"component": "definition", "props": {"groups": [{"snippet": "means any human disease or condition, or sign or symptom of a human disease or condition.", "samples": [{"hash": "eD5LjD1UoW5", "uri": "/contracts/eD5LjD1UoW5#indication", "label": "Acquisition and Strategic Collaboration Agreement (Salarius Pharmaceuticals, Inc.)", "score": 33.0328559875, "published": true}, {"hash": "9m7ph8xgnbN", "uri": "/contracts/9m7ph8xgnbN#indication", "label": "Collaboration and License Agreement (Epizyme, Inc.)", "score": 32.1457901001, "published": true}, {"hash": "lmSaGG2GbaE", "uri": "/contracts/lmSaGG2GbaE#indication", "label": "Distribution Agreement", "score": 31.3408622742, "published": true}], "size": 203, "snippet_links": [], "hash": "33f13de547a3e98ab21de44b70357b15", "id": 1}, {"snippet": "means a separate and distinct disease or medical condition in humans: (a) which a Product is intended to treat or prevent, as evidenced by the protocol for a clinical trial of such Product or by the proposed Product labeling in an NDA filed with a Regulatory Authority for such Product; or (b) which is contained in a Product\u2019s labeling approved by a Regulatory Authority as part of the Marketing Approval for such Product.", "samples": [{"hash": "KyCgt2EA1q", "uri": "/contracts/KyCgt2EA1q#indication", "label": "License Agreement (Tonix Pharmaceuticals Holding Corp.)", "score": 32.3538665771, "published": true}, {"hash": "f03N6W5ejAy", "uri": "/contracts/f03N6W5ejAy#indication", "label": "License Agreement (Virpax Pharmaceuticals, Inc.)", "score": 31.8856945038, "published": true}, {"hash": "50L8SYg9nHb", "uri": "/contracts/50L8SYg9nHb#indication", "label": "License Agreement (Provention Bio, Inc.)", "score": 29.3504447937, "published": true}], "size": 49, "snippet_links": [{"key": "separate-and-distinct", "type": "clause", "offset": [8, 29]}, {"key": "medical-condition", "type": "definition", "offset": [41, 58]}, {"key": "the-protocol", "type": "clause", "offset": [139, 151]}, {"key": "clinical-trial", "type": "clause", "offset": [158, 172]}, {"key": "product-labeling", "type": "definition", "offset": [208, 224]}, {"key": "regulatory-authority", "type": "definition", "offset": [248, 268]}, {"key": "contained-in", "type": "definition", "offset": [303, 315]}, {"key": "approved-by", "type": "definition", "offset": [337, 348]}, {"key": "marketing-approval", "type": "definition", "offset": [387, 405]}], "hash": "1a23ba02f3e09c14a15c860ad87ac53d", "id": 2}, {"snippet": "means [***].", "samples": [{"hash": "7vsZoOB1tgf", "uri": "/contracts/7vsZoOB1tgf#indication", "label": "Collaboration and License Agreement (Vir Biotechnology, Inc.)", "score": 37.3449707031, "published": true}, {"hash": "f6iCUW6ahoB", "uri": "/contracts/f6iCUW6ahoB#indication", "label": "Collaboration, License and Development Agreement (Ionis Pharmaceuticals Inc)", "score": 36.5756340027, "published": true}, {"hash": "7hMGGkEsXt0", "uri": "/contracts/7hMGGkEsXt0#indication", "label": "Strategic Collaboration Agreement (Ionis Pharmaceuticals Inc)", "score": 36.5756340027, "published": true}], "size": 47, "snippet_links": [], "hash": "42145ccc68badf480a8ed917c57dd5fc", "id": 3}, {"snippet": "means any disease or condition that can be treated, prevented or cured or the progression of which can be delayed and for which a Product is specifically Developed in order to obtain Regulatory Approval for use of such Product pursuant to an approved label claim.", "samples": [{"hash": "7rDzwd8ylPq", "uri": "/contracts/7rDzwd8ylPq#indication", "label": "Collaboration Agreement (Reata Pharmaceuticals Inc)", "score": 33.1587944031, "published": true}, {"hash": "8JfImJE3rPH", "uri": "/contracts/8JfImJE3rPH#indication", "label": "Collaboration Agreement (Reata Pharmaceuticals Inc)", "score": 27.1026687622, "published": true}, {"hash": "fOR6XG4rhlO", "uri": "/contracts/fOR6XG4rhlO#indication", "label": "Collaboration Agreement (Reata Pharmaceuticals Inc)", "score": 26.8836421967, "published": true}], "size": 44, "snippet_links": [{"key": "in-order-to", "type": "clause", "offset": [164, 175]}, {"key": "regulatory-approval", "type": "clause", "offset": [183, 202]}, {"key": "pursuant-to", "type": "definition", "offset": [227, 238]}, {"key": "approved-label", "type": "definition", "offset": [242, 256]}], "hash": "e70297a9c224b89209ea0d42f2393511", "id": 4}, {"snippet": "means any symptom, cause, or occurrence in a Sickness that points out the cause, diagnosis, course of treatment, or prognosis of the Sickness.", "samples": [{"hash": "56BHgeZoFjA", "uri": "https://www.unthsc.edu/students/wp-content/uploads/sites/26/2021-203104-1-Certificate.pdf", "label": "www.unthsc.edu", "score": 16.1570243835, "published": false}, {"hash": "cXct9fM01zD", "uri": "https://myahpcare.com/wp-content/uploads/2022-203104-1_UNT_DOM_Bro.pdf", "label": "myahpcare.com", "score": 11.283367157, "published": false}, {"hash": "hHhnnx9yXR7", "uri": "https://myahpcare.com/wp-content/uploads/2022-2023_UNT_Certificate.pdf", "label": "myahpcare.com", "score": 11.283367157, "published": false}], "size": 33, "snippet_links": [{"key": "course-of-treatment", "type": "clause", "offset": [92, 111]}], "hash": "ec61952747de189397a44c01b1348069", "id": 5}, {"snippet": "means a distinct type of human medical disease, disorder or condition.", "samples": [{"hash": "jtt3AxSwbt", "uri": "/contracts/jtt3AxSwbt#indication", "label": "Contingent Value Rights Agreement (Roche Holdings Inc)", "score": 36.8083496094, "published": true}, {"hash": "7Apt6XK0vrX", "uri": "/contracts/7Apt6XK0vrX#indication", "label": "Merger Agreement (89bio, Inc.)", "score": 36.7125244141, "published": true}, {"hash": "dqFyKRlegh8", "uri": "/contracts/dqFyKRlegh8#indication", "label": "Contingent Value Rights Agreement (Roche Holdings Inc)", "score": 36.0143737793, "published": true}], "size": 31, "snippet_links": [{"key": "type-of", "type": "definition", "offset": [17, 24]}], "hash": "f46be5bc0fbf2edebf9399c21c77c02a", "id": 6}, {"snippet": "means a generally acknowledged disease or condition, a significant manifestation of a disease or condition, or symptoms associated with a disease or condition or a risk for a disease or condition. For the avoidance of doubt, all variants of a single disease or condition (e.g., variants of colon cancer or variants of prostate cancer), whether classified by severity or otherwise, shall be treated as the same Indication for purposes of this Agreement.", "samples": [{"hash": "6wdx5m0F7w6", "uri": "/contracts/6wdx5m0F7w6#indication", "label": "License and Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "3eY9s4ns64l", "uri": "/contracts/3eY9s4ns64l#indication", "label": "License and Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "eCbXvMYhqMP", "uri": "/contracts/eCbXvMYhqMP#indication", "label": "License and Collaboration Agreement (Ziopharm Oncology Inc)", "score": 26.2484607697, "published": true}], "size": 30, "snippet_links": [{"key": "associated-with", "type": "definition", "offset": [120, 135]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [197, 223]}, {"key": "prostate-cancer", "type": "clause", "offset": [318, 333]}, {"key": "for-purposes-of-this-agreement", "type": "clause", "offset": [421, 451]}], "hash": "0fb8608752d1cdbce272e5e7682a5513", "id": 7}, {"snippet": "means a separately defined, well-categorized class of human disease or condition for which a separate MAA (including any extensions or supplements) is required to be filed with a Regulatory Authority. For clarity, if an MAA is approved for a Product in a particular Indication and patient population, a label expansion for such Product to include such Indication in a different patient population shall not be considered a separate Indication.", "samples": [{"hash": "kD2dgLVVlBK", "uri": "/contracts/kD2dgLVVlBK#indication", "label": "Exclusive License Agreement (Allarity Therapeutics, Inc.)", "score": 33.3723487854, "published": true}, {"hash": "2rLQVGEgVCt", "uri": "/contracts/2rLQVGEgVCt#indication", "label": "Exclusive License Agreement (Allarity Therapeutics, Inc.)", "score": 33.3723487854, "published": true}, {"hash": "8pt8E2gb56L", "uri": "/contracts/8pt8E2gb56L#indication", "label": "Collaboration and License Agreement (Verrica Pharmaceuticals Inc.)", "score": 32.3456535339, "published": true}], "size": 23, "snippet_links": [{"key": "class-of", "type": "definition", "offset": [45, 53]}, {"key": "a-separate", "type": "definition", "offset": [91, 101]}, {"key": "regulatory-authority", "type": "definition", "offset": [179, 199]}, {"key": "for-clarity", "type": "clause", "offset": [201, 212]}, {"key": "patient-population", "type": "definition", "offset": [281, 299]}, {"key": "label-expansion", "type": "definition", "offset": [303, 318]}], "hash": "29a005dc6aca5a1305f1f82d6c89e70f", "id": 8}, {"snippet": "means a separate and distinct disease, disorder or medical condition in humans that a Product is intended to treat, prevent, diagnose, monitor or ameliorate, as set forth in the IND or label for such Product, as approved by the applicable Medical Product Regulatory Authority. For clarity, the use of a Product to treat an expanded set or subset of patients for a disease, disorder or medical condition, when such Product has already received regulatory approval with respect to such disease, disorder or medical condition, shall not constitute a separate Indication with respect to such Product.", "samples": [{"hash": "lK79PruNd6D", "uri": "/contracts/lK79PruNd6D#indication", "label": "Asset Purchase Agreement (Xenon Pharmaceuticals Inc.)", "score": 28.5865840912, "published": true}, {"hash": "hMcJ3VfDP0Q", "uri": "https://investor.xenon-pharma.com/static-files/a8a6dbd9-6f19-4910-b4a4-4bedf458dff4", "label": "investor.xenon-pharma.com", "score": 7.9952087402, "published": false}, {"hash": "7HeoAtBkOux", "uri": "https://investor.xenon-pharma.com/static-files/2a0c0aff-5e47-4a04-a5ee-b9c20fda7c30", "label": "investor.xenon-pharma.com", "score": 6.7932920456, "published": false}], "size": 23, "snippet_links": [{"key": "separate-and-distinct", "type": "clause", "offset": [8, 29]}, {"key": "medical-condition", "type": "definition", "offset": [51, 68]}, {"key": "approved-by", "type": "definition", "offset": [212, 223]}, {"key": "the-applicable", "type": "clause", "offset": [224, 238]}, {"key": "medical-product-regulatory-authority", "type": "definition", "offset": [239, 275]}, {"key": "for-clarity", "type": "clause", "offset": [277, 288]}, {"key": "regulatory-approval", "type": "clause", "offset": [443, 462]}, {"key": "with-respect-to", "type": "clause", "offset": [463, 478]}], "hash": "5c6c28dfefca883a2abedf045abb9105", "id": 9}, {"snippet": "means each separate and distinct disease, disorder, illness, health condition, or interruption, cessation or disruption of a bodily function, system, tissue type or organ, for which Regulatory Approval is required.", "samples": [{"hash": "edUalaD1oSa", "uri": "/contracts/edUalaD1oSa#indication", "label": "Asset Purchase Agreement (Eliem Therapeutics, Inc.)", "score": 35.4859695435, "published": true}, {"hash": "h2o73Ukdm5W", "uri": "/contracts/h2o73Ukdm5W#indication", "label": "Exclusive License Agreement (CM Life Sciences III Inc.)", "score": 32.8247756958, "published": true}, {"hash": "lmXqpVrFx73", "uri": "/contracts/lmXqpVrFx73#indication", "label": "Discovery Collaboration and License Agreement (Harpoon Therapeutics, Inc.)", "score": 31.1930179596, "published": true}], "size": 22, "snippet_links": [{"key": "separate-and-distinct", "type": "clause", "offset": [11, 32]}, {"key": "health-condition", "type": "clause", "offset": [61, 77]}, {"key": "bodily-function", "type": "definition", "offset": [125, 140]}, {"key": "regulatory-approval", "type": "clause", "offset": [182, 201]}], "hash": "7ee08d21fed1170b58c9f183f67c1e15", "id": 10}], "next_curs": "ClcSUWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjMLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiITaW5kaWNhdGlvbiMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"snippet": "means any human disease or condition, or sign or symptom of a human disease or condition.", "size": 2429, "title": "Indication", "id": "indication", "examples": ["<strong>Indication</strong> of the Purchaser\u2019s ownership of a Receivable shall be deleted from or modified on the Seller\u2019s computer systems when, and only when, the Receivable shall have been paid in full or repurchased.", "<strong>Indication</strong> of the Collateral Agent\u2019s (for the benefit of the Secured Parties) security interest shall be deleted from or modified on the Borrower\u2019s computer systems when, and only when, the Collateral in question shall have been paid in full, the security interest under this Agreement has been released in accordance with its terms, upon such Collateral Obligation becoming a Repurchased Collateral Obligation or Substituted Collateral Obligation, or otherwise as expressly permitted by this Agreement.", "<strong>Indication</strong> of the Issuer\u2019s and the Indenture Trustee\u2019s interest in a Receivable shall be deleted from or modified on the Servicer\u2019s computer systems when, and only when, the related Receivable shall have been paid in full or repurchased."], "related": [["first-indication", "First Indication", "First <strong>Indication</strong>"], ["competing-product", "Competing Product", "Competing Product"], ["second-indication", "Second Indication", "Second <strong>Indication</strong>"], ["diagnostic-product", "Diagnostic Product", "Diagnostic Product"], ["reference-biological-product", "Reference biological product", "Reference biological product"]], "related_snippets": [], "updated": "2026-06-04T04:23:11+00:00"}, "json": true, "cursor": ""}}